RESUMEN
The complex organization of brain regions during development requires a three-dimensional approach to facilitate the visualization and quantification of dynamic changes taking place throughout this important period. Using the tissue clearing method combined with immunohistochemistry, three-dimensional (3D) lightsheet microscopy and a multiresolution registration technique, we provide the first 3D atlases of the main cholinergic (CH) and catecholaminergic (CA) systems in the mouse brain from embryonic day 12 (E12) to post-natal day 8 (P8). We report that in several brain structures, there is a logarithmic scale increase of choline acetyltransferase and tyrosine hydroxylase positive neurons from E18 to P8. In addition, a detailed voxel-wise analysis revealed abrupt modifications in the developmental trajectory of many brain structures during the transition from E18 to P0. Our atlases will not only facilitate developmental studies aimed at quantitatively determining the fate of CH or CA neurons in utero but also be used as an anatomical reference to quantify other neuronal populations present in the annotated regions. In the future, these maps will be a reliable tool to study developmental malformations associated with neurological and psychiatric disorders.
Asunto(s)
Colina O-Acetiltransferasa , Tirosina 3-Monooxigenasa , Animales , Encéfalo/metabolismo , Colina O-Acetiltransferasa/metabolismo , Colinérgicos , Humanos , Ratones , Neuronas/metabolismo , Tirosina 3-Monooxigenasa/metabolismoRESUMEN
The bisphosphonate, alendronate sodium (e.g. Fosamax) is a bone resorption inhibitor used to treat postmenopausal osteoporotic women and osseous Paget's disease. Esophagitis is one of the adverse effects (AE) associated to its use. Five (5) patients with alendronate-associated esophagitis assisted in the Gastroenterologic Center, Rosario, Argentina, between October 1996 and December 1999 are described. The aim is to correlate the clinical, endoscopic and histopathological findings in 5 women (ages 57-71) complaining for upper digestive symptoms (dysphagia, epigastralgia, retrosternal pain.). All had osteoporosis treated with alendronate 10 mg/day and received detailed instructions about how to take the medication. The time from the beginning of alendronate intake and the appearance of the symptoms was elapsed 30, 35, 67, 85 and 90 days. The esophagitis was graded according to the Savary-Miller Classification. The videoscopy disclosed esophagitis of III and IV grades. Three patients had also antral and antroduodenal lesions, one of them associated to Helicobacter Pylori. Anatomopathologic findings confirm esophagitis and esophagic ulceration. Some authors claim that bisphosphonates as a new class of gastrotoxic drugs with AE similar to aspirin. Even when it is administrated according to the instructions of the manufacturers it should be used with caution. Our contribution emphasize the importance of this AE and suggest measures to diminish or suppress them, and take into consideration those patients who are taking aspirin. With alendronate, as well as with other potentially corrosive agents, is very important to take in mind the measures to prevent AE.
Asunto(s)
Alendronato/efectos adversos , Esofagitis/inducido químicamente , Posmenopausia , Anciano , Alendronato/uso terapéutico , Esofagitis/diagnóstico , Femenino , Humanos , Persona de Mediana Edad , Osteoporosis Posmenopáusica/tratamiento farmacológico , Factores de TiempoRESUMEN
The bisphosphonate, alendronate sodium (e.g. Fosamax) is a bone resorption inhibitor used to treat postmenopausal osteoporotic women and osseous Pagets disease. Esophagitis is one of the adverse effects (AE) associated to its use. Five (5) patients with alendronate-associated esophagitis assisted in the Gastroenterologic Center, Rosario, Argentina, between October 1996 and December 1999 are described. The aim is to correlate the clinical, endoscopic and histopathological findings in 5 women (ages 57-71) complaining for upper digestive symptoms (dysphagia, epigastralgia, retrosternal pain.). All had osteoporosis treated with alendronate 10 mg/day and received detailed instructions about how to take the medication. The time from the beginning of alendronate intake and the appearance of the symptoms was elapsed 30, 35, 67, 85 and 90 days. The esophagitis was graded according to the Savary-Miller Classification. The videoscopy disclosed esophagitis of III and IV grades. Three patients had also antral and antroduodenal lesions, one of them associated to Helicobacter Pylori. Anatomopathologic findings confirm esophagitis and esophagic ulceration. Some authors claim that bisphosphonates as a new class of gastrotoxic drugs with AE similar to aspirin. Even when it is administrated according to the instructions of the manufacturers it should be used with caution. Our contribution emphasize the importance of this AE and suggest measures to diminish or suppress them, and take into consideration those patients who are taking aspirin. With alendronate, as well as with other potentially corrosive agents, is very important to take in mind the measures to prevent AE.
RESUMEN
The biphosphonate, alendronate sodium (e.g. Fosamax) is a bone resorption inhibitor used to treat posmenopausal osteoporotic women and osseous Pagets disease. Esophaghitis is one of the adverse effects (AE) associated to its use. Five (5) patients with alendronate-associated esophagitis assisted in the Gastroenterologic Center, Rosario, Argentina, between October 1996 and December 1999 are described. The aim is to correlate the clinical, endoscopic and histopathological findings in 5 women (ages 57-71) complained for upper digestive symptoms (disphagia, epigastrialgia, retroesternal pain). All had osteoporosis treated with alendronate 10 mg/day and received detailed instructions about how to take the medication. The time from the beginning of alendronate intake and the appearence of the symptoms was elapsed 30, 35, 67, 85 and 90 days. The esophagitis was graded according to the Savary-Miller Classification. The videoscopy disclosed esophagitis of III and IV grades. Three patients has also antral and antroduodenal lesions, one of them associated to Helicobacter pylori. Anatomopathological findings confirm esophagitis and esophagic ulceration. Some authors claim that disphosphonates as a new class of gastrotoxic drugs with AE similar to aspirin. Even when it is administrated according to the instructions of the manufactures it should be used with caution. Our contribution emphazise the importance of this AE and suggest measures to diminish or suppres them, and take into consideration those patients who are taking aspirin. With alendronate, as well as with other potentially corrosive agents, is very important to take in mind the measures to prevent AE. (Au)
Asunto(s)
Humanos , Femenino , Persona de Mediana Edad , Anciano , Esofagitis/inducido químicamente , Alendronato/efectos adversos , Posmenopausia , Esofagitis/diagnóstico , Alendronato/uso terapéutico , Osteoporosis Posmenopáusica/tratamiento farmacológico , Aspirina/efectos adversos , /efectos adversos , Factores de TiempoRESUMEN
The biphosphonate, alendronate sodium (e.g. Fosamax) is a bone resorption inhibitor used to treat posmenopausal osteoporotic women and osseous Paget's disease. Esophaghitis is one of the adverse effects (AE) associated to its use. Five (5) patients with alendronate-associated esophagitis assisted in the Gastroenterologic Center, Rosario, Argentina, between October 1996 and December 1999 are described. The aim is to correlate the clinical, endoscopic and histopathological findings in 5 women (ages 57-71) complained for upper digestive symptoms (disphagia, epigastrialgia, retroesternal pain). All had osteoporosis treated with alendronate 10 mg/day and received detailed instructions about how to take the medication. The time from the beginning of alendronate intake and the appearence of the symptoms was elapsed 30, 35, 67, 85 and 90 days. The esophagitis was graded according to the Savary-Miller Classification. The videoscopy disclosed esophagitis of III and IV grades. Three patients has also antral and antroduodenal lesions, one of them associated to Helicobacter pylori. Anatomopathological findings confirm esophagitis and esophagic ulceration. Some authors claim that disphosphonates as a new class of gastrotoxic drugs with AE similar to aspirin. Even when it is administrated according to the instructions of the manufactures it should be used with caution. Our contribution emphazise the importance of this AE and suggest measures to diminish or suppres them, and take into consideration those patients who are taking aspirin. With alendronate, as well as with other potentially corrosive agents, is very important to take in mind the measures to prevent AE.
Asunto(s)
Humanos , Femenino , Persona de Mediana Edad , Alendronato/efectos adversos , Esofagitis/inducido químicamente , Posmenopausia , Alendronato/uso terapéutico , Antiinflamatorios no Esteroideos/efectos adversos , Aspirina/efectos adversos , Esofagitis/diagnóstico , Osteoporosis Posmenopáusica/tratamiento farmacológico , Factores de TiempoRESUMEN
Introducción: La detección del H.p. en el estómago de pacientes vírgenes de tratamiento ha sido solucionada; un aspecto no resuelto, al menos en nuestro medio, es la pesquisa del H.p. luego de la terapéutica, para asegurar su erradicación. Objetivos: Utilizar una metodología sensible y específica para evaluar la presencia del H.p. en biopsias gástricas postratamiento, comparándola con otras técnicas similares clásicas. De esa manera, aumentando la precisión en el diagóstico, se podrá diferenciar la recrudescencia (falsa erradicación) de la reinfección y conocer el exacto porcentaje de curación. Materiales y Métodos: La PCR para H.p. fue realizada en 97 pacientes (62 hombres y 35 mujeres) con edad propedio de 49 años (+/- 14), en los cuales ya se había confirmado la erradicación por histología-Giemsa más CLO TEST. La metodología fue la siguiente: se realizaron 5 biopsias gástricas endoscópicas por paciente, 2 de antro, 2 de cuerpo, y 1 para CLO; todos los pacientes fueron estudiados luego de 6 ou 8 semanas de terminado el tratamiento y durante ese período no recibieron ninguna medicación. La metodología fue: las biopsias gástricas fueron fijadas en formol buffer al 10 por ciento, incluídas en parafina, y se colorearon con Giemsa y hematoxilina-eosina. El CLO TEST usado fue de Delta West Pty. Ltd. Bentley. La PCR se efectuó amplificando un fragmento de 296 pares de bases correspondiente al gen codificante del antígeno especie especifico de Helicobacter pylori, y la visualización del producto amplificado se realizó por electroforesis en gel de agarosa teñido con bromuro de etidio y U.V. Resultados: ninguno de estos pacientes presentaba úlcera gástrica o duodenal en el momento del control.Conclusiones: La PCR puede detectar secuencias de ADN especificas del H.p., incluso en su forma cocoide de resistencia, como se observan postratamiento. Las tinciones más utilizadas en biopsia (Giemsa/W-S) detectan aproximadamente 100000 microorganismos por ml; la PCR puede detectar 100, vale decir que es tres órdenes más sensible que la metodología clásica. En nuestra experiencia detectamos un 13 por ciento de falsos erradicados, los cuales clínicamente deberán ser considerados como recrudescencia y no como reinfección. (AU)
Asunto(s)
Adulto , Persona de Mediana Edad , Femenino , Humanos , Estudio Comparativo , Infecciones por Helicobacter/diagnóstico , Helicobacter pylori/aislamiento & purificación , Úlcera Gástrica/diagnóstico , Úlcera Duodenal/diagnóstico , Reacción en Cadena de la Polimerasa , Infecciones por Helicobacter/microbiología , Biopsia , Sensibilidad y Especificidad , Estudios Retrospectivos , ADN Bacteriano , Helicobacter pylori/genética , Úlcera Duodenal/microbiología , Úlcera Gástrica/microbiologíaRESUMEN
Introducción: La detección del H.p. en el estómago de pacientes vírgenes de tratamiento ha sido solucionada; un aspecto no resuelto, al menos en nuestro medio, es la pesquisa del H.p. luego de la terapéutica, para asegurar su erradicación. Objetivos: Utilizar una metodología sensible y específica para evaluar la presencia del H.p. en biopsias gástricas postratamiento, comparándola con otras técnicas similares clásicas. De esa manera, aumentando la precisión en el diagóstico, se podrá diferenciar la recrudescencia (falsa erradicación) de la reinfección y conocer el exacto porcentaje de curación. Materiales y Métodos: La PCR para H.p. fue realizada en 97 pacientes (62 hombres y 35 mujeres) con edad propedio de 49 años (+/- 14), en los cuales ya se había confirmado la erradicación por histología-Giemsa más CLO TEST. La metodología fue la siguiente: se realizaron 5 biopsias gástricas endoscópicas por paciente, 2 de antro, 2 de cuerpo, y 1 para CLO; todos los pacientes fueron estudiados luego de 6 ou 8 semanas de terminado el tratamiento y durante ese período no recibieron ninguna medicación. La metodología fue: las biopsias gástricas fueron fijadas en formol buffer al 10 por ciento, incluídas en parafina, y se colorearon con Giemsa y hematoxilina-eosina. El CLO TEST usado fue de Delta West Pty. Ltd. Bentley. La PCR se efectuó amplificando un fragmento de 296 pares de bases correspondiente al gen codificante del antígeno especie especifico de Helicobacter pylori, y la visualización del producto amplificado se realizó por electroforesis en gel de agarosa teñido con bromuro de etidio y U.V. Resultados: ninguno de estos pacientes presentaba úlcera gástrica o duodenal en el momento del control.Conclusiones: La PCR puede detectar secuencias de ADN especificas del H.p., incluso en su forma cocoide de resistencia, como se observan postratamiento. Las tinciones más utilizadas en biopsia (Giemsa/W-S) detectan aproximadamente 100000 microorganismos por ml; la PCR puede detectar 100, vale decir que es tres órdenes más sensible que la metodología clásica. En nuestra experiencia detectamos un 13 por ciento de falsos erradicados, los cuales clínicamente deberán ser considerados como recrudescencia y no como reinfección.
Asunto(s)
Adulto , Persona de Mediana Edad , Femenino , Humanos , Úlcera Duodenal/diagnóstico , Infecciones por Helicobacter/diagnóstico , Helicobacter pylori/aislamiento & purificación , Reacción en Cadena de la Polimerasa , Úlcera Gástrica/diagnóstico , Biopsia , ADN Bacteriano , Úlcera Duodenal/microbiología , Infecciones por Helicobacter/microbiología , Helicobacter pylori/genética , Estudios Retrospectivos , Sensibilidad y Especificidad , Úlcera Gástrica/microbiologíaRESUMEN
Experiments were performed to consider the use of conventional neonatal ventilators with assisted expiratory mechanism using ventilatory high frequency strategies. Gas exchange, hemodynamic state, and lung injury were also assessed. Twenty Albino Wistar rats, undergoing and acute lung lesion through physiological solution wash of the lungs were studied. Afterward, they were distributed into four groups according to the different ventilator strategies, based on the different pressure changes and the tidal volume, the baseline lung volume and the respiratory frequency. Group I, High Frequency Ventilation, with high baseline lung volumes (HFVh); group II, Conventional Mechanical Ventilation, with high baseline lung volume (CMVh), group III, High Frequency Ventilation, with low baseline lung volume (HFV1) and group IV Conventional Mechanical Ventilation, with low baseline lung volume (CMV1). Significant differences were found between group I (HFVh) and groups II (CMVh), III (HFV1) and IV (CMV1) as regards pO2, Artery/Alveolar relation to O2 (a/A), pCO2, arterial blood pressure and histopathologic lung lesion. The hypothesis concerning the decisive role of the baseline lung volume maintainence to minimize progressive damage caused by mechanical ventilation on a previously injured lung while attending ventilatory strategies that generate little pressure and volume cyclical changes was confirmed. We conclude that, high frequency mechanical ventilation is possible through conventional neonatal respirators with assisted expiratory mechanism.